BioSpace News Archive

New AI integration dramatically speeds medical image interpretation and model creation within Bioclinica’s imaging platform

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing.

Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin; therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in January, 2021.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the journal Nature Methods has selected spatially-resolved transcriptomics as their prestigious Method of the Year for 2020.

Willamette Surgery Center achieved a milestone in 2020, performing 200 total joint replacements as of November and finished the year with a record 254 total joint replacements.

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021, at 4:15 p.m. Eastern Time.

Noveome Biotherapeutics, Inc . , a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the publication of preclinical results evaluating the neuroprotective properties of fractionated and unfractionated ST266 in the journal PLOS ONE . The studies demonstrated that the comple

TRIGR Therapeutics, Inc. (“TRIGR”), a clinical stage biopharmaceutical company focused on the development of multi-targeted angiogenic and immunomodulatory bispecific antibodies for oncology and certain ischemic indications, announced today the publication of a manuscript in the International Journal of Molecular Sciences,

Medline and Tricol Biomedical, Inc. announced an exclusive agreement to distribute Hemostatic Control products in North America to acute care, emergency services, and cath lab providers.

The Allen Institute’s founding CEO, Allan Jones, Ph.D., announced he will step down after nearly 18 years with the organization.